A Gel Formulation Containing a New Recombinant Form of Manganese Superoxide Dismutase: A Clinical Experience Based on Compassionate Use-Safety of a Case Report
Background. We report a case of bilateral posterior subcapsular cataracts (PSCs) in a 24-year-old man with an allergic conjunctivitis history caused by a long-term therapy with glucocorticoids. Case Presentation. The patient showed a visual acuity of 9/10 for both eyes. He followed a therapy with ke...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Ophthalmological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2016/7240209 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561862400540672 |
|---|---|
| author | Lucia Grumetto Antonio Del Prete Giovanni Ortosecco Antonella Borrelli Salvatore Del Prete Aldo Mancini |
| author_facet | Lucia Grumetto Antonio Del Prete Giovanni Ortosecco Antonella Borrelli Salvatore Del Prete Aldo Mancini |
| author_sort | Lucia Grumetto |
| collection | DOAJ |
| description | Background. We report a case of bilateral posterior subcapsular cataracts (PSCs) in a 24-year-old man with an allergic conjunctivitis history caused by a long-term therapy with glucocorticoids. Case Presentation. The patient showed a visual acuity of 9/10 for both eyes. He followed a therapy with ketotifen and bilastine for four years. During the last six months before our evaluation, he was treated with chloramphenicol and betamethasone, interrupted for onset of cataracts and increased intraocular pressure. We treated him with ophthalmic gel preparation containing a new recombinant form of manganese superoxide dismutase (rMnSOD) at a concentration of 12.5 μg/mL, only for the right eye, while left eye was treated with standard protocol of Bendazac-lysine g 0.5. Conclusion. This case report shows the protective effects of rMnSOD versus PSC disease, probably due to the capacity of rMnSOD of countering free radical species. |
| format | Article |
| id | doaj-art-a2fb8c6ead554c4ea16e2454362107c8 |
| institution | Kabale University |
| issn | 2090-6722 2090-6730 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Ophthalmological Medicine |
| spelling | doaj-art-a2fb8c6ead554c4ea16e2454362107c82025-02-03T01:24:06ZengWileyCase Reports in Ophthalmological Medicine2090-67222090-67302016-01-01201610.1155/2016/72402097240209A Gel Formulation Containing a New Recombinant Form of Manganese Superoxide Dismutase: A Clinical Experience Based on Compassionate Use-Safety of a Case ReportLucia Grumetto0Antonio Del Prete1Giovanni Ortosecco2Antonella Borrelli3Salvatore Del Prete4Aldo Mancini5Department of Pharmacy, University of Naples Federico II, 80131 Naples, ItalyDepartment of Neurosciences and Reproductive and Dentistry Sciences, University of Naples Federico II, 80131 Naples, ItalyDepartment of Pharmacy, University of Naples Federico II, 80131 Naples, ItalyMolecular Biology and Viral Oncology Unit, Department of Experimental Oncology, National Institute of Cancer, IRCCS Foundation, Naples, ItalyDepartment of Neurosciences and Reproductive and Dentistry Sciences, University of Naples Federico II, 80131 Naples, ItalyLeadhexa Inc., QB3-UCSF, San Francisco, CA, USABackground. We report a case of bilateral posterior subcapsular cataracts (PSCs) in a 24-year-old man with an allergic conjunctivitis history caused by a long-term therapy with glucocorticoids. Case Presentation. The patient showed a visual acuity of 9/10 for both eyes. He followed a therapy with ketotifen and bilastine for four years. During the last six months before our evaluation, he was treated with chloramphenicol and betamethasone, interrupted for onset of cataracts and increased intraocular pressure. We treated him with ophthalmic gel preparation containing a new recombinant form of manganese superoxide dismutase (rMnSOD) at a concentration of 12.5 μg/mL, only for the right eye, while left eye was treated with standard protocol of Bendazac-lysine g 0.5. Conclusion. This case report shows the protective effects of rMnSOD versus PSC disease, probably due to the capacity of rMnSOD of countering free radical species.http://dx.doi.org/10.1155/2016/7240209 |
| spellingShingle | Lucia Grumetto Antonio Del Prete Giovanni Ortosecco Antonella Borrelli Salvatore Del Prete Aldo Mancini A Gel Formulation Containing a New Recombinant Form of Manganese Superoxide Dismutase: A Clinical Experience Based on Compassionate Use-Safety of a Case Report Case Reports in Ophthalmological Medicine |
| title | A Gel Formulation Containing a New Recombinant Form of Manganese Superoxide Dismutase: A Clinical Experience Based on Compassionate Use-Safety of a Case Report |
| title_full | A Gel Formulation Containing a New Recombinant Form of Manganese Superoxide Dismutase: A Clinical Experience Based on Compassionate Use-Safety of a Case Report |
| title_fullStr | A Gel Formulation Containing a New Recombinant Form of Manganese Superoxide Dismutase: A Clinical Experience Based on Compassionate Use-Safety of a Case Report |
| title_full_unstemmed | A Gel Formulation Containing a New Recombinant Form of Manganese Superoxide Dismutase: A Clinical Experience Based on Compassionate Use-Safety of a Case Report |
| title_short | A Gel Formulation Containing a New Recombinant Form of Manganese Superoxide Dismutase: A Clinical Experience Based on Compassionate Use-Safety of a Case Report |
| title_sort | gel formulation containing a new recombinant form of manganese superoxide dismutase a clinical experience based on compassionate use safety of a case report |
| url | http://dx.doi.org/10.1155/2016/7240209 |
| work_keys_str_mv | AT luciagrumetto agelformulationcontaininganewrecombinantformofmanganesesuperoxidedismutaseaclinicalexperiencebasedoncompassionateusesafetyofacasereport AT antoniodelprete agelformulationcontaininganewrecombinantformofmanganesesuperoxidedismutaseaclinicalexperiencebasedoncompassionateusesafetyofacasereport AT giovanniortosecco agelformulationcontaininganewrecombinantformofmanganesesuperoxidedismutaseaclinicalexperiencebasedoncompassionateusesafetyofacasereport AT antonellaborrelli agelformulationcontaininganewrecombinantformofmanganesesuperoxidedismutaseaclinicalexperiencebasedoncompassionateusesafetyofacasereport AT salvatoredelprete agelformulationcontaininganewrecombinantformofmanganesesuperoxidedismutaseaclinicalexperiencebasedoncompassionateusesafetyofacasereport AT aldomancini agelformulationcontaininganewrecombinantformofmanganesesuperoxidedismutaseaclinicalexperiencebasedoncompassionateusesafetyofacasereport AT luciagrumetto gelformulationcontaininganewrecombinantformofmanganesesuperoxidedismutaseaclinicalexperiencebasedoncompassionateusesafetyofacasereport AT antoniodelprete gelformulationcontaininganewrecombinantformofmanganesesuperoxidedismutaseaclinicalexperiencebasedoncompassionateusesafetyofacasereport AT giovanniortosecco gelformulationcontaininganewrecombinantformofmanganesesuperoxidedismutaseaclinicalexperiencebasedoncompassionateusesafetyofacasereport AT antonellaborrelli gelformulationcontaininganewrecombinantformofmanganesesuperoxidedismutaseaclinicalexperiencebasedoncompassionateusesafetyofacasereport AT salvatoredelprete gelformulationcontaininganewrecombinantformofmanganesesuperoxidedismutaseaclinicalexperiencebasedoncompassionateusesafetyofacasereport AT aldomancini gelformulationcontaininganewrecombinantformofmanganesesuperoxidedismutaseaclinicalexperiencebasedoncompassionateusesafetyofacasereport |